EGFR and neoplasm: Nevertheless, to increase the potency of EGFR-targeting therapies such as CAR T cells and BiTEs without further enhancing on-target/off-tumor toxicity, strategies to improve the specificity for EGFR in the tumor tissue are urgently needed.